Vaccine trial aims to shield HIV+ women from cervical cancer risk
NCT ID NCT03284866
Summary
This study tested whether the HPV vaccine could help prevent high-grade cervical lesions from developing or returning in women living with HIV. 536 HIV-positive women who also had HPV received either the actual vaccine or a placebo (saltwater shot) after their cervical lesions were treated. Researchers followed participants for two years to see if the vaccine reduced the chance of lesions coming back compared to the placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
African Cancer Institute at Stellenbosch
Cape Town, South Africa
-
Moi University School of Medicine
Eldoret, Kenya
-
UNC Project Malawi
Lilongwe, Malawi
-
Uganda Cancer Institute
Kampala, Uganda
-
University of Zimbabwe
Harare, Zimbabwe
-
University of the Witwatersrand
Johannesburg, South Africa
Conditions
Explore the condition pages connected to this study.